Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews

Ribeiro, Esther Letícia Amorim; Lima, Tácio de Mendonça; Vieira, Marcio Eduardo Bergamini; Storpirtis, Sílvia; Aguiar, Patrícia Melo

doi:10.1007/s00228-018-2498-1

Cited by 51 publications

(48 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aripiprazole displays high affinity for serotonin 5-HT1A and 5-HT2A receptors and dopamine D2 and D3 receptors [ 223 ]. The drug is unlikely to cause weight gain, sedation, or other changes in metabolism [ 226 , 230 , 231 , 232 ]. A 52-week trial of 478 patients with schizophrenia found that intramuscular injections of aripiprazole every four weeks (fixed at either 441 mg or 882 mg) was well-tolerated, making it a suitable treatment for schizophrenia [ 233 ].…”

Section: Role Of Antipsychoticsmentioning

confidence: 99%

Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia

Madireddy

2020

Brain Sciences

View full text Add to dashboard Cite

The biochemical integrity of the brain is paramount to the function of the central nervous system, and oxidative stress is a key contributor to cerebral biochemical impairment. Oxidative stress, which occurs when an imbalance arises between the production of reactive oxygen species (ROS) and the efficacy of the antioxidant defense mechanism, is believed to play a role in the pathophysiology of various brain disorders. One such disorder, schizophrenia, not only causes lifelong disability but also induces severe emotional distress; however, because of its onset in early adolescence or adulthood and its progressive development, consuming natural antioxidant products may help regulate the pathogenesis of schizophrenia. Therefore, elucidating the functions of ROS and dietary antioxidants in the pathogenesis of schizophrenia could help formulate improved therapeutic strategies for its prevention and treatment. This review focuses specifically on the roles of ROS and oxidative damage in the pathophysiology of schizophrenia, as well as the effects of nutrition, antipsychotic use, cognitive therapies, and quality of life on patients with schizophrenia. By improving our understanding of the effects of various nutrients on schizophrenia, it may become possible to develop nutritional strategies and supplements to treat the disorder, alleviate its symptoms, and facilitate long-term recovery.

show abstract

Section: Role Of Antipsychoticsmentioning

confidence: 99%

Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia

Madireddy

2020

Brain Sciences

View full text Add to dashboard Cite

show abstract

“…Thus, drugs such as aripiprazole, which can modulate the dopaminergic system, might be beneficial for reducing craving, rewarding effects, and relapse [16]. These characteristics, together with its well-established efficacy for the treatment of schizophrenia, the lower risk of extrapyramidal side effects compared to first-generation antipsychotics, and the lower risk of metabolic side effects compared to most second-generation antipsychotics [17], make aripiprazole an attractive alternative for the treatment of patients with schizophrenia with coexisting SUDs. Evidence from randomized clinical trials and laboratory studies has suggested that oral aripiprazole could be efficacious for the management of alcohol [18,19] or cocaine dependence [20,21].…”

Section: Introductionmentioning

confidence: 99%

Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study

Szerman

Basurte-Villamor

Vega³

et al. 2020

Drugs - Real World Outcomes

View full text Add to dashboard Cite

Aim To evaluate the efficacy and impact of long-acting injectable (LAI) aripiprazole in patients with schizophrenia with a coexisting substance use disorder (SUD). Patients and methods A multicenter, observational, descriptive and retrospective study was conducted in patients with a DSM-5 diagnosis of schizophrenia who had a coexisting SUD and were treated with LAI-aripiprazole. Disease severity was evaluated with the Clinical Global Impression (CGI) severity scale for schizophrenia, daily functioning and disability were evaluated with the World Health Organisation Disability Assessment Scale (WHODAS-2.0), and the severity of the addiction was evaluated with the Severity of Dependence Scale (SDS). Results The sample included 40 patients. Overall, after 6 months of treatment with LAI-aripiprazole at a dose of 400 mg/4 weeks in 77.5% of the patients, we observed significant improvement in the psychopathological symptoms, with a reduction of over 30% in the scores of the five CGI-severity scales. The WHODAS-2.0 mean (standard deviation) score was also significantly reduced from 57.6 (8.2) to 42.3 (4.3) points (p < 0.001). Regarding SUDs, after 6 months of treatment, substance use was stopped in 5 of the 9 patients with cocaine use disorder and in 3 of the 16 patients with alcohol abuse disorder. A significant reduction in the severity of the dependence was observed only in the subgroups of participants with cocaine and alcohol use disorders. Conclusion Our study suggests that once-monthly LAI-aripiprazole retains its antipsychotic efficacy in patients with schizophrenia and a coexisting SUD and could be useful for the management of cocaine or alcohol use disorders in this population.

show abstract

“…Clinical application of aripiprazole includes also bipolar disorder, major depression, obsessive-compulsive disorder, and autism. Aripiprazole is characterized by efficacy similar to that of both typical and atypical antipsychotic drugs (except olanzapine and amisulpride) [ 112 ]. Aripiprazole resulted in considerably lower weight gain and lower changes in glucose and cholesterol levels in comparison to clozapine, risperidone, and olanzapine [ 112 ].…”

Section: Multi-target Compounds To Treat Schizophreniamentioning

confidence: 99%

“…Aripiprazole is characterized by efficacy similar to that of both typical and atypical antipsychotic drugs (except olanzapine and amisulpride) [ 112 ]. Aripiprazole resulted in considerably lower weight gain and lower changes in glucose and cholesterol levels in comparison to clozapine, risperidone, and olanzapine [ 112 ]. Moreover, aripiprazole led to weaker EPS, less use of antiparkinsonian drugs, and akathisia, in comparison to typical antipsychotic drugs and risperidone [ 112 ].…”

Section: Multi-target Compounds To Treat Schizophreniamentioning

confidence: 99%

“…Aripiprazole resulted in considerably lower weight gain and lower changes in glucose and cholesterol levels in comparison to clozapine, risperidone, and olanzapine [ 112 ]. Moreover, aripiprazole led to weaker EPS, less use of antiparkinsonian drugs, and akathisia, in comparison to typical antipsychotic drugs and risperidone [ 112 ]. Furthermore, aripiprazole is characterized by better tolerability compared to other antipsychotics [ 113 ].…”

Section: Multi-target Compounds To Treat Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

Multi-Target Approach for Drug Discovery against Schizophrenia

Kondej

Stępnicki

Kaczor

2018

IJMS

View full text Add to dashboard Cite

Polypharmacology is nowadays considered an increasingly crucial aspect in discovering new drugs as a number of original single-target drugs have been performing far behind expectations during the last ten years. In this scenario, multi-target drugs are a promising approach against polygenic diseases with complex pathomechanisms such as schizophrenia. Indeed, second generation or atypical antipsychotics target a number of aminergic G protein-coupled receptors (GPCRs) simultaneously. Novel strategies in drug design and discovery against schizophrenia focus on targets beyond the dopaminergic hypothesis of the disease and even beyond the monoamine GPCRs. In particular these approaches concern proteins involved in glutamatergic and cholinergic neurotransmission, challenging the concept of antipsychotic activity without dopamine D2 receptor involvement. Potentially interesting compounds include ligands interacting with glycine modulatory binding pocket on N-methyl-d-aspartate (NMDA) receptors, positive allosteric modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, positive allosteric modulators of metabotropic glutamatergic receptors, agonists and positive allosteric modulators of α7 nicotinic receptors, as well as muscarinic receptor agonists. In this review we discuss classical and novel drug targets for schizophrenia, cover benefits and limitations of current strategies to design multi-target drugs and show examples of multi-target ligands as antipsychotics, including marketed drugs, substances in clinical trials, and other investigational compounds.

show abstract

Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews

Abstract: Aripiprazole exhibited efficacy similar to that of other antipsychotic drugs and a better safety profile than that of typical (i.e., less some extrapyramidal side effects) and atypical (i.e., less metabolic changes) antipsychotic drugs.

Cited by 51 publications

References 42 publications

Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia

Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia

Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study

Multi-Target Approach for Drug Discovery against Schizophrenia

Contact Info

Product

Resources

About